gene_symbol,study_id,assay_id,log2fc,adj_pvalue,test_group,ref_group,go_terms
IL36A,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',10.700,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424; GO:0009615
DEFB4A,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',10.200,0.00e+00,lesional skin; psoriasis,normal; normal,
SPRR2C,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',9.400,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424; GO:0009615
IL19,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',9.300,0.00e+00,lesional skin; psoriasis,normal; normal,
PI3,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',8.900,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424; GO:0009615
AC130360.2,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',8.600,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424; GO:0009615
HSPD1P3,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',8.600,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424; GO:0009615
VNN3,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',8.300,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424; GO:0009615
S100A12,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',8.100,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424; GO:0009615
SPRR2F,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',8.100,0.00e+00,lesional skin; psoriasis,normal; normal,
CXCL11,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',8.000,4.89e-12,normal; injection of interferon gamma,normal; none,GO:0009615
CXCL8,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',7.900,0.00e+00,lesional skin; psoriasis,normal; normal,
TCN1,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',7.800,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424; GO:0009615
CXCL11,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',7.700,4.70e-12,psoriasis; injection of interferon gamma,psoriasis; none,GO:0009615
TMPRSS11D,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',7.600,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424; GO:0009615
SPRR2B,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',7.300,0.00e+00,lesional skin; psoriasis,normal; normal,
PI3,E-GEOD-52471,'psoriasis' vs 'normal' in 'Affy RNA amplification kit',7.200,2.51e-18,Affy RNA amplification kit; psoriasis,Affy RNA amplification kit; normal,GO:0070268; GO:0031424; GO:0009615
TNIP3,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',7.100,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424; GO:0009615
S100A7A,E-GEOD-41662,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',6.900,3.01e-22,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
SPRR2A,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',6.900,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424; GO:0009615
S100A7A,E-GEOD-53552,'lesional' vs 'non-lesional' in 'none' at '0 day',6.800,8.64e-23,0 day; lesional; none,0 day; non-lesional; none,GO:0070268; GO:0031424; GO:0009615
KRT6C,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',6.800,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424; GO:0009615
S100A7,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',6.800,0.00e+00,lesional skin; psoriasis,normal; normal,
S100A9,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',6.800,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424; GO:0009615
S100A7A,E-GEOD-34248,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',6.700,3.32e-07,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
CXCL10,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',6.600,1.88e-06,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
CXCL9,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',6.600,1.84e-10,normal; injection of interferon gamma,normal; none,GO:0009615
S100A9,E-GEOD-52471,'psoriasis' vs 'normal' in 'Affy RNA amplification kit',6.600,4.08e-11,Affy RNA amplification kit; psoriasis,Affy RNA amplification kit; normal,GO:0070268; GO:0031424; GO:0009615
S100A8,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',6.600,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424; GO:0009615
SERPINB3,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',6.600,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424; GO:0009615
CXCL10,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',6.500,1.00e-08,normal; injection of interferon gamma,normal; none,GO:0009615
S100A12,E-GEOD-53552,'lesional' vs 'non-lesional' in 'none' at '0 day',6.500,1.68e-25,0 day; lesional; none,0 day; non-lesional; none,GO:0070268; GO:0031424; GO:0009615
S100A12,E-GEOD-50790,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',6.500,4.70e-04,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
S100A12,E-GEOD-41662,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',6.500,8.98e-26,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
TCN1,E-GEOD-50790,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',6.500,1.48e-03,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
SERPINB4,E-GEOD-41745,'lesional' vs 'non-lesional',6.400,0.00e+00,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
ADGRF1,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',6.400,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424; GO:0009615
CXCL1,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',6.400,0.00e+00,lesional skin; psoriasis,normal; normal,
AKR1B10P1,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',6.300,0.00e+00,lesional skin; psoriasis,normal; normal,
CXCL9,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',6.200,5.48e-12,psoriasis; injection of interferon gamma,psoriasis; none,GO:0009615
SERPINB4,E-GEOD-41662,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',6.200,3.58e-19,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
AKR1B10,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',6.200,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424; GO:0009615
HEPHL1,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',6.200,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424
IDO1,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',6.100,1.87e-14,psoriasis; injection of interferon gamma,psoriasis; none,
SERPINB4,E-GEOD-53552,'lesional' vs 'non-lesional' in 'none' at '0 day',6.100,1.12e-19,0 day; lesional; none,0 day; non-lesional; none,GO:0070268; GO:0031424; GO:0009615
TCN1,E-GEOD-26866,'lesional' vs 'non-lesional' in 'one-cycle cDNA synthesis from bulk tissue',6.100,6.20e-03,lesional; one-cycle cDNA synthesis from bulk tissue,non-lesional; one-cycle cDNA synthesis from bulk tissue,GO:0070268; GO:0031424; GO:0009615
RSAD2,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',6.000,1.87e-14,psoriasis; injection of interferon gamma,psoriasis; none,GO:0070268; GO:0031424; GO:0009615
IDO1,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',5.900,1.14e-11,normal; injection of interferon gamma,normal; none,
S100A12,E-GEOD-30999,'lesional' vs 'non-lesional',5.900,0.00e+00,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
SERPINB3,E-GEOD-53552,'lesional' vs 'non-lesional' in 'none' at '0 day',5.900,8.29e-17,0 day; lesional; none,0 day; non-lesional; none,GO:0070268; GO:0031424; GO:0009615
SERPINB3,E-GEOD-41662,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',5.900,1.72e-16,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
SPRR2C,E-GEOD-50790,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',5.900,6.77e-04,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
SPRR2C,E-GEOD-52471,'psoriasis' vs 'normal' in 'Affy RNA amplification kit',5.900,6.35e-20,Affy RNA amplification kit; psoriasis,Affy RNA amplification kit; normal,GO:0070268; GO:0031424; GO:0009615
CXCL13,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',5.900,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0009615
GDA,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',5.900,0.00e+00,lesional skin; psoriasis,normal; normal,
RSAD2,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',5.800,1.14e-11,normal; injection of interferon gamma,normal; none,GO:0070268; GO:0031424; GO:0009615
SERPINB4,E-GEOD-52471,'psoriasis' vs 'normal' in 'Affy RNA amplification kit',5.800,6.35e-16,Affy RNA amplification kit; psoriasis,Affy RNA amplification kit; normal,GO:0070268; GO:0031424; GO:0009615
SPRR2D,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',5.800,0.00e+00,lesional skin; psoriasis,normal; normal,
MMP1,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',5.700,1.96e-06,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
CCL8,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',5.700,1.06e-13,psoriasis; injection of interferon gamma,psoriasis; none,GO:0009615
S100A12,E-GEOD-26866,'lesional' vs 'non-lesional' in 'one-cycle cDNA synthesis from bulk tissue',5.700,6.61e-03,lesional; one-cycle cDNA synthesis from bulk tissue,non-lesional; one-cycle cDNA synthesis from bulk tissue,GO:0070268; GO:0031424; GO:0009615
TCN1,E-GEOD-26866,'lesional' vs 'non-lesional' in 'two-cycle cDNA synthesis from bulk tissue',5.700,5.57e-03,lesional; two-cycle cDNA synthesis from bulk tissue,non-lesional; two-cycle cDNA synthesis from bulk tissue,GO:0070268; GO:0031424; GO:0009615
AKR1B10,E-GEOD-52471,'psoriasis' vs 'normal' in 'Affy RNA amplification kit',5.700,5.79e-18,Affy RNA amplification kit; psoriasis,Affy RNA amplification kit; normal,GO:0070268; GO:0031424; GO:0009615
TCN1,E-GEOD-52471,'psoriasis' vs 'normal' in 'Affy RNA amplification kit',5.700,2.77e-16,Affy RNA amplification kit; psoriasis,Affy RNA amplification kit; normal,GO:0070268; GO:0031424; GO:0009615
SERPINB4,E-GEOD-52471,'psoriasis' vs 'normal' in 'Ovation RNA Amplification V2 kit',5.700,3.86e-06,Ovation RNA Amplification V2 kit; psoriasis,Ovation RNA Amplification V2 kit; normal,GO:0070268; GO:0031424; GO:0009615
IL20,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',5.700,0.00e+00,lesional skin; psoriasis,normal; normal,
CXCL13,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',5.600,5.07e-05,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
SPRR2C,E-GEOD-41662,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',5.600,6.60e-22,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
IL36G,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',5.600,0.00e+00,lesional skin; psoriasis,normal; normal,
LTF,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',5.600,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424; GO:0009615
CCL8,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',5.500,9.73e-12,normal; injection of interferon gamma,normal; none,GO:0009615
APOBEC3A,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',5.500,1.96e-11,psoriasis; injection of interferon gamma,psoriasis; none,
SPRR2C,E-GEOD-53552,'lesional' vs 'non-lesional' in 'none' at '0 day',5.500,1.16e-21,0 day; lesional; none,0 day; non-lesional; none,GO:0070268; GO:0031424; GO:0009615
IGFL1,E-GEOD-50790,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',5.500,1.78e-03,lesional,non-lesional,
SPRR3,E-GEOD-50790,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',5.500,4.81e-04,lesional,non-lesional,
TCN1,E-GEOD-41662,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',5.500,8.53e-18,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
IL36G,E-GEOD-52471,'psoriasis' vs 'normal' in 'Affy RNA amplification kit',5.500,6.38e-19,Affy RNA amplification kit; psoriasis,Affy RNA amplification kit; normal,
SERPINB3,E-GEOD-52471,'psoriasis' vs 'normal' in 'Affy RNA amplification kit',5.500,5.06e-12,Affy RNA amplification kit; psoriasis,Affy RNA amplification kit; normal,GO:0070268; GO:0031424; GO:0009615
CERNA2,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',5.500,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424; GO:0009615
AIM2,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',5.400,1.58e-06,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
TCN1,E-GEOD-53552,'lesional' vs 'non-lesional' in 'none' at '0 day',5.400,3.78e-18,0 day; lesional; none,0 day; non-lesional; none,GO:0070268; GO:0031424; GO:0009615
C10orf99,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',5.400,0.00e+00,lesional skin; psoriasis,normal; normal,
NOS2,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',5.400,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424; GO:0009615
CXCL9,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',5.300,1.43e-04,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
OAS2,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',5.300,1.07e-12,normal; injection of interferon gamma,normal; none,GO:0009615
SERPINB3,E-GEOD-41745,'lesional' vs 'non-lesional',5.300,0.00e+00,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
CXCL8,E-GEOD-50790,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',5.300,6.77e-04,lesional,non-lesional,
MMP12,E-GEOD-50790,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',5.300,2.60e-03,lesional,non-lesional,
SERPINB4,E-GEOD-34248,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',5.300,1.44e-08,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
SPRR2C,E-GEOD-34248,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',5.300,3.43e-08,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
S100A12,E-GEOD-52471,'psoriasis' vs 'normal' in 'Affy RNA amplification kit',5.300,6.91e-16,Affy RNA amplification kit; psoriasis,Affy RNA amplification kit; normal,GO:0070268; GO:0031424; GO:0009615
KRT16,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',5.300,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424; GO:0009615
ADAMDEC1,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',5.200,2.62e-05,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0070268; GO:0031424; GO:0009615
CXCL11,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',5.200,2.95e-04,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
OASL,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',5.200,1.33e-06,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0070268; GO:0031424; GO:0009615
ISG15,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',5.200,2.16e-10,normal; injection of interferon gamma,normal; none,GO:0009615
OAS2,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',5.200,1.87e-14,psoriasis; injection of interferon gamma,psoriasis; none,GO:0009615
PI3,E-GEOD-53552,'lesional' vs 'non-lesional' in 'none' at '0 day',5.200,1.38e-18,0 day; lesional; none,0 day; non-lesional; none,GO:0070268; GO:0031424; GO:0009615
S100A9,E-GEOD-53552,'lesional' vs 'non-lesional' in 'none' at '0 day',5.200,2.48e-18,0 day; lesional; none,0 day; non-lesional; none,GO:0070268; GO:0031424; GO:0009615
PI3,E-GEOD-41662,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',5.200,3.35e-18,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
S100A9,E-GEOD-41662,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',5.200,7.15e-18,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
AL034376.2,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',5.200,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424; GO:0009615
LCE3D,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',5.200,0.00e+00,lesional skin; psoriasis,normal; normal,
LCE3E,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',5.200,0.00e+00,lesional skin; psoriasis,normal; normal,
RHCG,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',5.200,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424; GO:0009615
RP4-529N6.2,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',5.200,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424; GO:0009615
PLAC8,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',5.100,1.68e-06,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
HERC6,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',5.100,1.14e-11,normal; injection of interferon gamma,normal; none,GO:0009615
IFI44L,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',5.100,6.56e-11,normal; injection of interferon gamma,normal; none,GO:0070268; GO:0031424; GO:0009615
HERC6,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',5.100,2.39e-13,psoriasis; injection of interferon gamma,psoriasis; none,GO:0009615
ISG20,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',5.100,1.87e-14,psoriasis; injection of interferon gamma,psoriasis; none,GO:0009615
TCN1,E-GEOD-30999,'lesional' vs 'non-lesional',5.100,0.00e+00,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
TMPRSS11D,E-GEOD-50790,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',5.100,4.81e-04,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
VNN3,E-GEOD-50790,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',5.100,6.13e-05,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
SERPINB3,E-GEOD-52471,'psoriasis' vs 'normal' in 'Ovation RNA Amplification V2 kit',5.100,5.25e-06,Ovation RNA Amplification V2 kit; psoriasis,Ovation RNA Amplification V2 kit; normal,GO:0070268; GO:0031424; GO:0009615
HRNR,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',5.100,0.00e+00,lesional skin; psoriasis,normal; normal,
IGFL1,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',5.100,0.00e+00,lesional skin; psoriasis,normal; normal,
S100A12,E-GEOD-41663,'skin lesion' vs 'normal skin' in 'none' at '0 weeks',5.100,1.62e-08,none; skin lesion; 0 week,none; normal; 0 week,GO:0070268; GO:0031424; GO:0009615
TCN1,E-GEOD-41663,'skin lesion' vs 'normal skin' in 'none' at '0 weeks',5.100,2.19e-08,none; skin lesion; 0 week,none; normal; 0 week,GO:0070268; GO:0031424; GO:0009615
GZMB,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',5.000,1.88e-06,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
ISG15,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',5.000,1.58e-06,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
S100A12,E-GEOD-41745,'lesional' vs 'non-lesional',5.000,0.00e+00,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
S100A9,E-GEOD-34248,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',5.000,8.01e-09,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
AKR1B15,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',5.000,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424; GO:0009615
EPGN,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',5.000,0.00e+00,lesional skin; psoriasis,normal; normal,
S100A9,E-GEOD-16161,'atopic dermatitis' vs 'normal',4.900,3.52e-05,atopic dermatitis,normal,GO:0070268; GO:0031424; GO:0009615
RSAD2,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',4.900,6.45e-06,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0070268; GO:0031424; GO:0009615
APOBEC3A,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',4.900,1.18e-09,normal; injection of interferon gamma,normal; none,
ISG20,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',4.900,4.12e-12,normal; injection of interferon gamma,normal; none,GO:0009615
ISG15,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',4.900,2.89e-12,psoriasis; injection of interferon gamma,psoriasis; none,GO:0009615
SPRR2C,E-GEOD-30999,'lesional' vs 'non-lesional',4.900,0.00e+00,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
RHCG,E-GEOD-26866,'lesional' vs 'non-lesional' in 'one-cycle cDNA synthesis from bulk tissue',4.900,6.20e-03,lesional; one-cycle cDNA synthesis from bulk tissue,non-lesional; one-cycle cDNA synthesis from bulk tissue,GO:0070268; GO:0031424; GO:0009615
AKR1B10,E-GEOD-50790,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',4.900,6.37e-04,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
S100A12,E-GEOD-52471,'psoriasis' vs 'normal' in 'Ovation RNA Amplification V2 kit',4.900,1.07e-05,Ovation RNA Amplification V2 kit; psoriasis,Ovation RNA Amplification V2 kit; normal,GO:0070268; GO:0031424; GO:0009615
IFI44L,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',4.800,1.87e-14,psoriasis; injection of interferon gamma,psoriasis; none,GO:0070268; GO:0031424; GO:0009615
PI3,E-GEOD-41745,'lesional' vs 'non-lesional',4.800,1.49e-31,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
S100A12,E-GEOD-26866,'lesional' vs 'non-lesional' in 'two-cycle cDNA synthesis from bulk tissue',4.800,6.56e-03,lesional; two-cycle cDNA synthesis from bulk tissue,non-lesional; two-cycle cDNA synthesis from bulk tissue,GO:0070268; GO:0031424; GO:0009615
CXCL8,E-GEOD-41662,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',4.800,7.36e-15,lesional,non-lesional,
S100A9,E-GEOD-50790,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',4.800,2.30e-03,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
CCL20,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',4.800,0.00e+00,lesional skin; psoriasis,normal; normal,
TCN1,E-GEOD-41745,'lesional' vs 'non-lesional',4.700,4.63e-38,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
VNN3,E-GEOD-30999,'lesional' vs 'non-lesional',4.700,0.00e+00,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
CXCL8,E-GEOD-53552,'lesional' vs 'non-lesional' in 'none' at '0 day',4.700,1.02e-14,0 day; lesional; none,0 day; non-lesional; none,
LCN2,E-GEOD-53552,'lesional' vs 'non-lesional' in 'none' at '0 day',4.700,3.04e-19,0 day; lesional; none,0 day; non-lesional; none,
VNN3,E-GEOD-53552,'lesional' vs 'non-lesional' in 'none' at '0 day',4.700,1.08e-25,0 day; lesional; none,0 day; non-lesional; none,GO:0070268; GO:0031424; GO:0009615
LCN2,E-GEOD-41662,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',4.700,3.58e-19,lesional,non-lesional,
RHCG,E-GEOD-50790,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',4.700,4.81e-04,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
S100A12,E-GEOD-34248,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',4.700,2.50e-07,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
VNN3,E-GEOD-41662,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',4.700,4.47e-25,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
CHAC1,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',4.700,0.00e+00,lesional skin; psoriasis,normal; normal,
GBP1,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',4.600,3.67e-11,normal; injection of interferon gamma,normal; none,GO:0070268; GO:0031424; GO:0002376; GO:0009615
IRF1,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',4.600,4.89e-12,normal; injection of interferon gamma,normal; none,
OAS3,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',4.600,5.40e-11,normal; injection of interferon gamma,normal; none,GO:0009615
OASL,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',4.600,6.91e-14,psoriasis; injection of interferon gamma,psoriasis; none,GO:0070268; GO:0031424; GO:0009615
PLAAT4,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',4.600,8.10e-14,psoriasis; injection of interferon gamma,psoriasis; none,
RARRES3,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',4.600,8.10e-14,psoriasis; injection of interferon gamma,psoriasis; none,
WARS,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',4.600,6.05e-14,psoriasis; injection of interferon gamma,psoriasis; none,
WARS1,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',4.600,6.05e-14,psoriasis; injection of interferon gamma,psoriasis; none,
SERPINB4,E-GEOD-30999,'lesional' vs 'non-lesional',4.600,0.00e+00,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
SPRR2C,E-GEOD-41745,'lesional' vs 'non-lesional',4.600,2.01e-28,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
SERPINB3,E-GEOD-34248,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',4.600,2.90e-08,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
LTF,E-GEOD-52471,'psoriasis' vs 'normal' in 'Ovation RNA Amplification V2 kit',4.600,1.95e-05,Ovation RNA Amplification V2 kit; psoriasis,Ovation RNA Amplification V2 kit; normal,GO:0070268; GO:0031424; GO:0009615
ABCG4,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',4.600,0.00e+00,lesional skin; psoriasis,normal; normal,
SPRR2G,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',4.600,0.00e+00,lesional skin; psoriasis,normal; normal,
IFIT3,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',4.500,1.07e-12,normal; injection of interferon gamma,normal; none,GO:0070268; GO:0031424; GO:0009615
OASL,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',4.500,4.89e-12,normal; injection of interferon gamma,normal; none,GO:0070268; GO:0031424; GO:0009615
PLAAT4,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',4.500,5.38e-11,normal; injection of interferon gamma,normal; none,
RARRES3,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',4.500,5.38e-11,normal; injection of interferon gamma,normal; none,
SOCS1,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',4.500,1.58e-09,normal; injection of interferon gamma,normal; none,
WARS,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',4.500,1.11e-10,normal; injection of interferon gamma,normal; none,
WARS1,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',4.500,1.11e-10,normal; injection of interferon gamma,normal; none,
IFIT3,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',4.500,7.19e-15,psoriasis; injection of interferon gamma,psoriasis; none,GO:0070268; GO:0031424; GO:0009615
CHAC1,E-GEOD-50790,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',4.500,8.50e-04,lesional,non-lesional,
OASL,E-GEOD-50790,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',4.500,1.31e-03,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
SERPINB4,E-GEOD-50790,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',4.500,4.70e-04,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
HPSE,E-GEOD-52471,'psoriasis' vs 'normal' in 'Affy RNA amplification kit',4.500,1.14e-15,Affy RNA amplification kit; psoriasis,Affy RNA amplification kit; normal,GO:0070268; GO:0031424; GO:0009615
KRT6A,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',4.500,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424; GO:0009615
KYNU,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',4.500,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424; GO:0009615
OASL,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',4.500,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424; GO:0009615
PLA2G4D,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',4.500,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424; GO:0009615
VNN3,E-GEOD-41663,'skin lesion' vs 'normal skin' in 'none' at '0 weeks',4.500,2.20e-08,none; skin lesion; 0 week,none; normal; 0 week,GO:0070268; GO:0031424; GO:0009615
CCL8,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',4.400,2.62e-05,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
APOL1,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',4.400,1.54e-13,normal; injection of interferon gamma,normal; none,GO:0070268; GO:0031424; GO:0009615
MX1,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',4.400,9.97e-11,normal; injection of interferon gamma,normal; none,GO:0009615
PLA1A,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',4.400,4.89e-12,normal; injection of interferon gamma,normal; none,GO:0009615
IRF1,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',4.400,5.71e-14,psoriasis; injection of interferon gamma,psoriasis; none,
MX1,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',4.400,1.90e-13,psoriasis; injection of interferon gamma,psoriasis; none,GO:0009615
S100A9,E-GEOD-41745,'lesional' vs 'non-lesional',4.400,1.28e-25,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
ATP12A,E-GEOD-53552,'lesional' vs 'non-lesional' in 'none' at '0 day',4.400,3.11e-19,0 day; lesional; none,0 day; non-lesional; none,
IL36G,E-GEOD-53552,'lesional' vs 'non-lesional' in 'none' at '0 day',4.400,3.99e-19,0 day; lesional; none,0 day; non-lesional; none,
KRT16,E-GEOD-26866,'lesional' vs 'non-lesional' in 'two-cycle cDNA synthesis from bulk tissue',4.400,5.57e-03,lesional; two-cycle cDNA synthesis from bulk tissue,non-lesional; two-cycle cDNA synthesis from bulk tissue,GO:0070268; GO:0031424; GO:0009615
SPRR2C,E-GEOD-26866,'lesional' vs 'non-lesional' in 'two-cycle cDNA synthesis from bulk tissue',4.400,6.51e-03,lesional; two-cycle cDNA synthesis from bulk tissue,non-lesional; two-cycle cDNA synthesis from bulk tissue,GO:0070268; GO:0031424; GO:0009615
ATP12A,E-GEOD-41662,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',4.400,9.24e-19,lesional,non-lesional,
IL36A,E-GEOD-50790,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',4.400,1.48e-03,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
IL36G,E-GEOD-41662,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',4.400,8.85e-19,lesional,non-lesional,
GJB2,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',4.400,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424; GO:0009615
LCN2,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',4.400,0.00e+00,lesional skin; psoriasis,normal; normal,
RND1,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',4.400,0.00e+00,lesional skin; psoriasis,normal; normal,
SLC6A14,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',4.400,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424; GO:0009615
TRIM15,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',4.400,0.00e+00,lesional skin; psoriasis,normal; normal,
TMPRSS11D,E-GEOD-41663,'skin lesion' vs 'normal skin' in 'none' at '0 weeks',4.400,4.47e-09,none; skin lesion; 0 week,none; normal; 0 week,GO:0070268; GO:0031424; GO:0009615
IFIH1,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',4.300,3.34e-11,normal; injection of interferon gamma,normal; none,GO:0009615
APOL1,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',4.300,1.87e-14,psoriasis; injection of interferon gamma,psoriasis; none,GO:0070268; GO:0031424; GO:0009615
OAS3,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',4.300,4.15e-14,psoriasis; injection of interferon gamma,psoriasis; none,GO:0009615
SOCS1,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',4.300,4.35e-12,psoriasis; injection of interferon gamma,psoriasis; none,
RHCG,E-GEOD-26866,'lesional' vs 'non-lesional' in 'two-cycle cDNA synthesis from bulk tissue',4.300,5.57e-03,lesional; two-cycle cDNA synthesis from bulk tissue,non-lesional; two-cycle cDNA synthesis from bulk tissue,GO:0070268; GO:0031424; GO:0009615
RGS1,E-GEOD-26866,'lesional' vs 'non-lesional' in 'two-cycle cDNA synthesis from sliced tissue section',4.300,6.75e-03,lesional; two-cycle cDNA synthesis from sliced tissue section,non-lesional; two-cycle cDNA synthesis from sliced tissue section,
MMP1,E-GEOD-50790,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',4.300,2.09e-03,lesional,non-lesional,GO:0009615
SOST,E-GEOD-50790,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',4.300,2.33e-03,lesional,non-lesional,
H4C3,E-GEOD-52471,'psoriasis' vs 'normal' in 'Ovation RNA Amplification V2 kit',4.300,3.86e-06,Ovation RNA Amplification V2 kit; psoriasis,Ovation RNA Amplification V2 kit; normal,
HIST1H4C,E-GEOD-52471,'psoriasis' vs 'normal' in 'Ovation RNA Amplification V2 kit',4.300,3.86e-06,Ovation RNA Amplification V2 kit; psoriasis,Ovation RNA Amplification V2 kit; normal,
ADAMDEC1,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',4.300,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424; GO:0009615
CTA-384D8.35,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',4.300,0.00e+00,lesional skin; psoriasis,normal; normal,
KLHDC7B-DT,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',4.300,0.00e+00,lesional skin; psoriasis,normal; normal,
TEX101,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',4.300,0.00e+00,lesional skin; psoriasis,normal; normal,
U62317.1,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',4.300,0.00e+00,lesional skin; psoriasis,normal; normal,
U62317.2,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',4.300,0.00e+00,lesional skin; psoriasis,normal; normal,
OAS2,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',4.200,3.44e-06,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
PLA1A,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',4.200,6.62e-05,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
IFI35,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',4.200,9.97e-11,normal; injection of interferon gamma,normal; none,
KRT16,E-GEOD-41745,'lesional' vs 'non-lesional',4.200,0.00e+00,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
KRT6A,E-GEOD-41745,'lesional' vs 'non-lesional',4.200,0.00e+00,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
KRT6C,E-GEOD-41745,'lesional' vs 'non-lesional',4.200,1.40e-45,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
TMPRSS11D,E-GEOD-53552,'lesional' vs 'non-lesional' in 'none' at '0 day',4.200,3.78e-22,0 day; lesional; none,0 day; non-lesional; none,GO:0070268; GO:0031424; GO:0009615
ATP12A,E-GEOD-50790,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',4.200,2.15e-03,lesional,non-lesional,
HPSE,E-GEOD-41662,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',4.200,2.34e-14,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
PI3,E-GEOD-34248,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',4.200,9.10e-09,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
PRSS27,E-GEOD-50790,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',4.200,4.70e-04,lesional,non-lesional,
TMPRSS11D,E-GEOD-41662,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',4.200,2.73e-21,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
IFIT1,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',4.100,1.07e-06,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
ISG20,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',4.100,7.21e-05,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
TYMP,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',4.100,5.40e-10,normal; injection of interferon gamma,normal; none,GO:0070268; GO:0031424; GO:0009615
GBP1,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',4.100,1.22e-11,psoriasis; injection of interferon gamma,psoriasis; none,GO:0070268; GO:0031424; GO:0002376; GO:0009615
IFI35,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',4.100,5.18e-14,psoriasis; injection of interferon gamma,psoriasis; none,
IFIH1,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',4.100,3.82e-12,psoriasis; injection of interferon gamma,psoriasis; none,GO:0009615
TYMP,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',4.100,1.51e-12,psoriasis; injection of interferon gamma,psoriasis; none,GO:0070268; GO:0031424; GO:0009615
S100A7A,E-GEOD-30999,'lesional' vs 'non-lesional',4.100,0.00e+00,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
TMPRSS11D,E-GEOD-41745,'lesional' vs 'non-lesional',4.100,0.00e+00,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
AKR1B10,E-GEOD-53552,'lesional' vs 'non-lesional' in 'none' at '0 day',4.100,7.33e-20,0 day; lesional; none,0 day; non-lesional; none,GO:0070268; GO:0031424; GO:0009615
HPSE,E-GEOD-53552,'lesional' vs 'non-lesional' in 'none' at '0 day',4.100,1.19e-14,0 day; lesional; none,0 day; non-lesional; none,GO:0070268; GO:0031424; GO:0009615
KYNU,E-GEOD-26866,'lesional' vs 'non-lesional' in 'one-cycle cDNA synthesis from bulk tissue',4.100,7.00e-03,lesional; one-cycle cDNA synthesis from bulk tissue,non-lesional; one-cycle cDNA synthesis from bulk tissue,GO:0070268; GO:0031424; GO:0009615
AKR1B10,E-GEOD-41662,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',4.100,1.98e-19,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
ATP12A,E-GEOD-34248,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',4.100,3.56e-06,lesional,non-lesional,
CXCL8,E-GEOD-34248,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',4.100,6.01e-07,lesional,non-lesional,
SELL,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',4.000,1.10e-04,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
TDO2,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',4.000,9.66e-05,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
IFI44,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',4.000,2.87e-10,normal; injection of interferon gamma,normal; none,GO:0009615
PLA1A,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',4.000,6.99e-11,psoriasis; injection of interferon gamma,psoriasis; none,GO:0009615
SELL,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',4.000,1.46e-11,psoriasis; injection of interferon gamma,psoriasis; none,GO:0009615
AKR1B10,E-GEOD-30999,'lesional' vs 'non-lesional',4.000,0.00e+00,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
ATP12A,E-GEOD-30999,'lesional' vs 'non-lesional',4.000,0.00e+00,lesional,non-lesional,
SERPINB3,E-GEOD-30999,'lesional' vs 'non-lesional',4.000,0.00e+00,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
TMPRSS11D,E-GEOD-30999,'lesional' vs 'non-lesional',4.000,0.00e+00,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
DSC2,E-GEOD-26866,'lesional' vs 'non-lesional' in 'one-cycle cDNA synthesis from bulk tissue',4.000,6.59e-03,lesional; one-cycle cDNA synthesis from bulk tissue,non-lesional; one-cycle cDNA synthesis from bulk tissue,GO:0070268; GO:0031424; GO:0009615
KRT16,E-GEOD-26866,'lesional' vs 'non-lesional' in 'one-cycle cDNA synthesis from bulk tissue',4.000,7.00e-03,lesional; one-cycle cDNA synthesis from bulk tissue,non-lesional; one-cycle cDNA synthesis from bulk tissue,GO:0070268; GO:0031424; GO:0009615
AKR1B10,E-GEOD-34248,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',4.000,9.10e-09,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
CHI3L2,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',4.000,0.00e+00,lesional skin; psoriasis,normal; normal,
PRSS27,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',4.000,0.00e+00,lesional skin; psoriasis,normal; normal,
UGT1A7,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',4.000,0.00e+00,lesional skin; psoriasis,normal; normal,
AKR1B10,E-GEOD-16161,'atopic dermatitis' vs 'normal',3.900,5.60e-06,atopic dermatitis,normal,GO:0070268; GO:0031424; GO:0009615
MX1,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.900,1.33e-06,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
SAMD9,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.900,1.70e-05,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0070268; GO:0031424; GO:0009615
XAF1,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',3.900,8.99e-10,normal; injection of interferon gamma,normal; none,GO:0070268; GO:0031424; GO:0009615
CXCL8,E-GEOD-30999,'lesional' vs 'non-lesional',3.900,2.54e-41,lesional,non-lesional,
OASL,E-GEOD-30999,'lesional' vs 'non-lesional',3.900,0.00e+00,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
AKR1B10,E-GEOD-26866,'lesional' vs 'non-lesional' in 'one-cycle cDNA synthesis from bulk tissue',3.900,6.59e-03,lesional; one-cycle cDNA synthesis from bulk tissue,non-lesional; one-cycle cDNA synthesis from bulk tissue,GO:0070268; GO:0031424; GO:0009615
KLK13,E-GEOD-26866,'lesional' vs 'non-lesional' in 'one-cycle cDNA synthesis from bulk tissue',3.900,6.82e-03,lesional; one-cycle cDNA synthesis from bulk tissue,non-lesional; one-cycle cDNA synthesis from bulk tissue,GO:0070268; GO:0031424; GO:0009615
KYNU,E-GEOD-26866,'lesional' vs 'non-lesional' in 'two-cycle cDNA synthesis from bulk tissue',3.900,6.51e-03,lesional; two-cycle cDNA synthesis from bulk tissue,non-lesional; two-cycle cDNA synthesis from bulk tissue,GO:0070268; GO:0031424; GO:0009615
ADAMDEC1,E-GEOD-50790,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',3.900,1.66e-03,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
CTA-384D8.35,E-GEOD-50790,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',3.900,1.78e-03,lesional,non-lesional,
CXCL13,E-GEOD-41662,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',3.900,3.51e-15,lesional,non-lesional,GO:0009615
IGFL1,E-GEOD-41662,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',3.900,1.25e-17,lesional,non-lesional,
IL26,E-GEOD-50790,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',3.900,4.81e-04,lesional,non-lesional,
KLHDC7B-DT,E-GEOD-50790,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',3.900,1.78e-03,lesional,non-lesional,
KLK6,E-GEOD-41662,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',3.900,3.11e-13,lesional,non-lesional,
LCN2,E-GEOD-34248,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',3.900,2.89e-06,lesional,non-lesional,
U62317.1,E-GEOD-50790,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',3.900,1.78e-03,lesional,non-lesional,
U62317.2,E-GEOD-50790,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',3.900,1.78e-03,lesional,non-lesional,
VNN3,E-GEOD-34248,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',3.900,9.54e-07,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
KLK13,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',3.900,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424; GO:0009615
TRIM10,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',3.900,0.00e+00,lesional skin; psoriasis,normal; normal,
CXCL13,E-GEOD-41663,'skin lesion' vs 'normal skin' in 'none' at '0 weeks',3.900,2.19e-08,none; skin lesion; 0 week,none; normal; 0 week,GO:0009615
IFI44L,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.800,1.96e-06,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0070268; GO:0031424; GO:0009615
MMP9,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.800,5.60e-04,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
RTP4,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.800,8.59e-05,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
SERPINB4,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.800,1.13e-04,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0070268; GO:0031424; GO:0009615
TLR7,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.800,1.12e-04,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
IFIT1,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',3.800,8.85e-10,normal; injection of interferon gamma,normal; none,GO:0009615
LAMP3,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',3.800,1.44e-10,normal; injection of interferon gamma,normal; none,GO:0070268; GO:0031424; GO:0009615
MX2,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',3.800,2.36e-11,normal; injection of interferon gamma,normal; none,GO:0009615
PLAC8,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',3.800,2.35e-08,normal; injection of interferon gamma,normal; none,GO:0009615
IFIT1,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',3.800,1.12e-11,psoriasis; injection of interferon gamma,psoriasis; none,GO:0009615
MX2,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',3.800,1.46e-12,psoriasis; injection of interferon gamma,psoriasis; none,GO:0009615
XAF1,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',3.800,7.88e-13,psoriasis; injection of interferon gamma,psoriasis; none,GO:0070268; GO:0031424; GO:0009615
KYNU,E-GEOD-30999,'lesional' vs 'non-lesional',3.800,0.00e+00,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
LTF,E-GEOD-41745,'lesional' vs 'non-lesional',3.800,5.92e-33,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
RHCG,E-GEOD-30999,'lesional' vs 'non-lesional',3.800,0.00e+00,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
C10orf99,E-GEOD-53552,'lesional' vs 'non-lesional' in 'none' at '0 day',3.800,6.42e-13,0 day; lesional; none,0 day; non-lesional; none,
CXCL13,E-GEOD-53552,'lesional' vs 'non-lesional' in 'none' at '0 day',3.800,1.75e-15,0 day; lesional; none,0 day; non-lesional; none,GO:0009615
IGFL1,E-GEOD-53552,'lesional' vs 'non-lesional' in 'none' at '0 day',3.800,2.02e-17,0 day; lesional; none,0 day; non-lesional; none,
KLK6,E-GEOD-53552,'lesional' vs 'non-lesional' in 'none' at '0 day',3.800,4.26e-13,0 day; lesional; none,0 day; non-lesional; none,
C10orf99,E-GEOD-41662,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',3.800,1.80e-12,lesional,non-lesional,
CXCL1,E-GEOD-50790,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',3.800,1.66e-03,lesional,non-lesional,
LCN2,E-GEOD-50790,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',3.800,1.89e-03,lesional,non-lesional,
AAK1,E-GEOD-52471,'psoriasis' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.800,6.47e-06,Ovation RNA Amplification V2 kit; psoriasis,Ovation RNA Amplification V2 kit; normal,
GZMB,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',3.800,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0009615
KCNK10,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',3.800,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424; GO:0009615
ATP12A,E-GEOD-41663,'skin lesion' vs 'normal skin' in 'none' at '0 weeks',3.800,1.37e-08,none; skin lesion; 0 week,none; normal; 0 week,
OASL,E-GEOD-41663,'skin lesion' vs 'normal skin' in 'none' at '0 weeks',3.800,8.70e-09,none; skin lesion; 0 week,none; normal; 0 week,GO:0070268; GO:0031424; GO:0009615
C1QB,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.700,3.05e-05,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
CD69,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.700,2.70e-04,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
SERPINB3,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.700,9.58e-05,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0070268; GO:0031424; GO:0009615
RTP4,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',3.700,8.06e-11,normal; injection of interferon gamma,normal; none,GO:0009615
SELL,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',3.700,5.10e-08,normal; injection of interferon gamma,normal; none,GO:0009615
LAMP3,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',3.700,7.08e-11,psoriasis; injection of interferon gamma,psoriasis; none,GO:0070268; GO:0031424; GO:0009615
RTP4,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',3.700,2.24e-13,psoriasis; injection of interferon gamma,psoriasis; none,GO:0009615
GJB2,E-GEOD-41745,'lesional' vs 'non-lesional',3.700,0.00e+00,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
HPSE,E-GEOD-30999,'lesional' vs 'non-lesional',3.700,0.00e+00,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
S100A9,E-GEOD-30999,'lesional' vs 'non-lesional',3.700,0.00e+00,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
TNIP3,E-GEOD-30999,'lesional' vs 'non-lesional',3.700,0.00e+00,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
KYNU,E-GEOD-53552,'lesional' vs 'non-lesional' in 'none' at '0 day',3.700,9.97e-25,0 day; lesional; none,0 day; non-lesional; none,GO:0070268; GO:0031424; GO:0009615
DSC2,E-GEOD-26866,'lesional' vs 'non-lesional' in 'two-cycle cDNA synthesis from bulk tissue',3.700,6.74e-03,lesional; two-cycle cDNA synthesis from bulk tissue,non-lesional; two-cycle cDNA synthesis from bulk tissue,GO:0070268; GO:0031424; GO:0009615
CXCL13,E-GEOD-34248,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',3.700,2.20e-06,lesional,non-lesional,GO:0009615
KYNU,E-GEOD-41662,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',3.700,5.66e-24,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
HPSE,E-GEOD-52471,'psoriasis' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.700,1.12e-05,Ovation RNA Amplification V2 kit; psoriasis,Ovation RNA Amplification V2 kit; normal,GO:0070268; GO:0031424; GO:0009615
ACP7,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',3.700,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424; GO:0009615
AL078590.2,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',3.700,0.00e+00,lesional skin; psoriasis,normal; normal,
CT69,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',3.700,0.00e+00,lesional skin; psoriasis,normal; normal,
IFI27,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',3.700,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0009615
RP11-557H15.3,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',3.700,0.00e+00,lesional skin; psoriasis,normal; normal,
ZC3H12A,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',3.700,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424; GO:0009615
LCN2,E-GEOD-41663,'skin lesion' vs 'normal skin' in 'none' at '0 weeks',3.700,2.16e-08,none; skin lesion; 0 week,none; normal; 0 week,
APOL6,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.600,8.16e-06,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
CD8A,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.600,1.03e-04,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
GNLY,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.600,1.37e-04,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
KMO,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.600,9.66e-05,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
MX2,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.600,1.68e-06,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
TFEC,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.600,2.51e-04,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
IFI27,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',3.600,1.04e-10,normal; injection of interferon gamma,normal; none,GO:0009615
TAP2,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',3.600,4.82e-09,normal; injection of interferon gamma,normal; none,
IFI44,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',3.600,4.27e-12,psoriasis; injection of interferon gamma,psoriasis; none,GO:0009615
SECTM1,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',3.600,3.01e-11,psoriasis; injection of interferon gamma,psoriasis; none,
CXCL1,E-GEOD-30999,'lesional' vs 'non-lesional',3.600,4.55e-43,lesional,non-lesional,
CXCL13,E-GEOD-30999,'lesional' vs 'non-lesional',3.600,0.00e+00,lesional,non-lesional,GO:0009615
IL36G,E-GEOD-30999,'lesional' vs 'non-lesional',3.600,0.00e+00,lesional,non-lesional,
LCN2,E-GEOD-30999,'lesional' vs 'non-lesional',3.600,0.00e+00,lesional,non-lesional,
PLA2G4D,E-GEOD-41745,'lesional' vs 'non-lesional',3.600,1.67e-34,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
TNIP3,E-GEOD-41745,'lesional' vs 'non-lesional',3.600,2.40e-14,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
CXCL1,E-GEOD-41662,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',3.600,6.28e-14,lesional,non-lesional,
IGFL1,E-GEOD-34248,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',3.600,2.98e-06,lesional,non-lesional,
KLK13,E-GEOD-41662,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',3.600,1.53e-15,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
PRPF19,E-GEOD-52471,'psoriasis' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.600,6.33e-06,Ovation RNA Amplification V2 kit; psoriasis,Ovation RNA Amplification V2 kit; normal,
TYMP,E-GEOD-52471,'psoriasis' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.600,1.07e-05,Ovation RNA Amplification V2 kit; psoriasis,Ovation RNA Amplification V2 kit; normal,GO:0070268; GO:0031424; GO:0009615
ARSF,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',3.600,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424; GO:0009615
LINC01215,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',3.600,0.00e+00,lesional skin; psoriasis,normal; normal,
LRRC55,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',3.600,0.00e+00,lesional skin; psoriasis,normal; normal,
OAS2,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',3.600,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0009615
SPRR1B,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',3.600,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424; GO:0009615
SPRR2E,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',3.600,0.00e+00,lesional skin; psoriasis,normal; normal,
TNIP3,E-GEOD-41663,'skin lesion' vs 'normal skin' in 'none' at '0 weeks',3.600,6.30e-08,none; skin lesion; 0 week,none; normal; 0 week,GO:0070268; GO:0031424; GO:0009615
AL139020.1,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.500,5.85e-04,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
GZMK,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.500,9.67e-05,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
IFIT3,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.500,1.09e-05,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0070268; GO:0031424; GO:0009615
STAP1,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.500,1.17e-04,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
TCL1A,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.500,5.85e-04,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
OAS1,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',3.500,1.53e-09,normal; injection of interferon gamma,normal; none,GO:0070268; GO:0031424; GO:0009615
PLSCR1,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',3.500,6.56e-11,normal; injection of interferon gamma,normal; none,GO:0009615
SAMD9,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',3.500,6.34e-11,normal; injection of interferon gamma,normal; none,GO:0070268; GO:0031424; GO:0009615
SECTM1,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',3.500,1.66e-09,normal; injection of interferon gamma,normal; none,
SLAMF8,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',3.500,1.86e-12,psoriasis; injection of interferon gamma,psoriasis; none,
S100A8,E-GEOD-41745,'lesional' vs 'non-lesional',3.500,2.83e-13,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
CXCL1,E-GEOD-53552,'lesional' vs 'non-lesional' in 'none' at '0 day',3.500,1.47e-13,0 day; lesional; none,0 day; non-lesional; none,
KLK13,E-GEOD-53552,'lesional' vs 'non-lesional' in 'none' at '0 day',3.500,1.87e-15,0 day; lesional; none,0 day; non-lesional; none,GO:0070268; GO:0031424; GO:0009615
TNIP3,E-GEOD-53552,'lesional' vs 'non-lesional' in 'none' at '0 day',3.500,1.50e-13,0 day; lesional; none,0 day; non-lesional; none,GO:0070268; GO:0031424; GO:0009615
AKR1B10,E-GEOD-26866,'lesional' vs 'non-lesional' in 'two-cycle cDNA synthesis from bulk tissue',3.500,5.57e-03,lesional; two-cycle cDNA synthesis from bulk tissue,non-lesional; two-cycle cDNA synthesis from bulk tissue,GO:0070268; GO:0031424; GO:0009615
IL36G,E-GEOD-34248,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',3.500,1.44e-08,lesional,non-lesional,
SERPINB3,E-GEOD-50790,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',3.500,6.13e-05,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
SPRR2A,E-GEOD-41662,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',3.500,3.14e-13,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
TEX101,E-GEOD-50790,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',3.500,6.13e-05,lesional,non-lesional,
TNIP3,E-GEOD-41662,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',3.500,3.18e-13,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
ATP12A,E-GEOD-52471,'psoriasis' vs 'normal' in 'Affy RNA amplification kit',3.500,9.09e-10,Affy RNA amplification kit; psoriasis,Affy RNA amplification kit; normal,
IFI27,E-GEOD-52471,'psoriasis' vs 'normal' in 'Affy RNA amplification kit',3.500,7.66e-15,Affy RNA amplification kit; psoriasis,Affy RNA amplification kit; normal,GO:0009615
RHCG,E-GEOD-52471,'psoriasis' vs 'normal' in 'Affy RNA amplification kit',3.500,1.92e-10,Affy RNA amplification kit; psoriasis,Affy RNA amplification kit; normal,GO:0070268; GO:0031424; GO:0009615
SLC6A14,E-GEOD-52471,'psoriasis' vs 'normal' in 'Affy RNA amplification kit',3.500,2.77e-10,Affy RNA amplification kit; psoriasis,Affy RNA amplification kit; normal,GO:0070268; GO:0031424; GO:0009615
TREX2,E-GEOD-52471,'psoriasis' vs 'normal' in 'Affy RNA amplification kit',3.500,9.44e-13,Affy RNA amplification kit; psoriasis,Affy RNA amplification kit; normal,
EHBP1L1,E-GEOD-52471,'psoriasis' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.500,8.86e-06,Ovation RNA Amplification V2 kit; psoriasis,Ovation RNA Amplification V2 kit; normal,
CYP24A1,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',3.500,0.00e+00,lesional skin; psoriasis,normal; normal,
FABP5,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',3.500,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424; GO:0009615
HYAL4,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',3.500,0.00e+00,lesional skin; psoriasis,normal; normal,
HYAL4,E-GEOD-41663,'skin lesion' vs 'normal skin' in 'none' at '0 weeks',3.500,2.19e-08,none; skin lesion; 0 week,none; normal; 0 week,
IL36A,E-GEOD-41663,'skin lesion' vs 'normal skin' in 'none' at '0 weeks',3.500,1.54e-08,none; skin lesion; 0 week,none; normal; 0 week,GO:0070268; GO:0031424; GO:0009615
BST2,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.400,1.08e-05,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
CD48,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.400,1.12e-04,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
CCL2,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',3.400,5.60e-09,normal; injection of interferon gamma,normal; none,
CTSS,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',3.400,1.04e-08,normal; injection of interferon gamma,normal; none,
DDX60,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',3.400,1.20e-09,normal; injection of interferon gamma,normal; none,GO:0009615
RGS1,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',3.400,1.65e-09,normal; injection of interferon gamma,normal; none,
UBE2L6,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',3.400,4.89e-12,normal; injection of interferon gamma,normal; none,GO:0009615
CCL2,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',3.400,6.13e-11,psoriasis; injection of interferon gamma,psoriasis; none,
CX3CL1,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',3.400,1.87e-14,psoriasis; injection of interferon gamma,psoriasis; none,
OAS1,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',3.400,1.17e-10,psoriasis; injection of interferon gamma,psoriasis; none,GO:0070268; GO:0031424; GO:0009615
SAMD9,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',3.400,1.33e-12,psoriasis; injection of interferon gamma,psoriasis; none,GO:0070268; GO:0031424; GO:0009615
CCL20,E-GEOD-30999,'lesional' vs 'non-lesional',3.400,1.75e-43,lesional,non-lesional,
CTA-384D8.35,E-GEOD-30999,'lesional' vs 'non-lesional',3.400,0.00e+00,lesional,non-lesional,
HEPHL1,E-GEOD-41745,'lesional' vs 'non-lesional',3.400,8.50e-14,lesional,non-lesional,GO:0070268; GO:0031424
IGFL1,E-GEOD-30999,'lesional' vs 'non-lesional',3.400,0.00e+00,lesional,non-lesional,
KLHDC7B-DT,E-GEOD-30999,'lesional' vs 'non-lesional',3.400,0.00e+00,lesional,non-lesional,
U62317.1,E-GEOD-30999,'lesional' vs 'non-lesional',3.400,0.00e+00,lesional,non-lesional,
U62317.2,E-GEOD-30999,'lesional' vs 'non-lesional',3.400,0.00e+00,lesional,non-lesional,
RHCG,E-GEOD-53552,'lesional' vs 'non-lesional' in 'none' at '0 day',3.400,4.36e-16,0 day; lesional; none,0 day; non-lesional; none,GO:0070268; GO:0031424; GO:0009615
SERPINB13,E-GEOD-26866,'lesional' vs 'non-lesional' in 'two-cycle cDNA synthesis from bulk tissue',3.400,7.15e-03,lesional; two-cycle cDNA synthesis from bulk tissue,non-lesional; two-cycle cDNA synthesis from bulk tissue,GO:0070268; GO:0031424; GO:0009615
ADAMDEC1,E-GEOD-34248,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',3.400,8.82e-06,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
CCL20,E-GEOD-34248,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',3.400,1.91e-06,lesional,non-lesional,
CCL20,E-GEOD-41662,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',3.400,8.97e-13,lesional,non-lesional,
RHCG,E-GEOD-41662,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',3.400,5.21e-15,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
TMPRSS11D,E-GEOD-34248,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',3.400,5.47e-07,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
KLK13,E-GEOD-52471,'psoriasis' vs 'normal' in 'Affy RNA amplification kit',3.400,7.60e-11,Affy RNA amplification kit; psoriasis,Affy RNA amplification kit; normal,GO:0070268; GO:0031424; GO:0009615
CTSC,E-GEOD-52471,'psoriasis' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.400,6.67e-06,Ovation RNA Amplification V2 kit; psoriasis,Ovation RNA Amplification V2 kit; normal,
IFI27,E-GEOD-52471,'psoriasis' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.400,2.35e-05,Ovation RNA Amplification V2 kit; psoriasis,Ovation RNA Amplification V2 kit; normal,GO:0009615
KRT6A,E-GEOD-52471,'psoriasis' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.400,2.43e-05,Ovation RNA Amplification V2 kit; psoriasis,Ovation RNA Amplification V2 kit; normal,GO:0070268; GO:0031424; GO:0009615
TGM1,E-GEOD-52471,'psoriasis' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.400,9.12e-06,Ovation RNA Amplification V2 kit; psoriasis,Ovation RNA Amplification V2 kit; normal,GO:0070268; GO:0031424; GO:0009615
VNN3,E-GEOD-52471,'psoriasis' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.400,1.03e-05,Ovation RNA Amplification V2 kit; psoriasis,Ovation RNA Amplification V2 kit; normal,GO:0070268; GO:0031424; GO:0009615
CD274,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',3.400,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424; GO:0009615
HERC6,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',3.400,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0009615
RGS1,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',3.400,0.00e+00,lesional skin; psoriasis,normal; normal,
RHCG,E-GEOD-41663,'skin lesion' vs 'normal skin' in 'none' at '0 weeks',3.400,1.65e-08,none; skin lesion; 0 week,none; normal; 0 week,GO:0070268; GO:0031424; GO:0009615
S100A8,E-GEOD-16161,'atopic dermatitis' vs 'normal',3.300,1.21e-05,atopic dermatitis,normal,GO:0070268; GO:0031424; GO:0009615
IFI27,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.300,1.68e-06,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
KRT16,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.300,1.80e-04,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0070268; GO:0031424; GO:0009615
OAS3,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.300,5.39e-06,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
PI3,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.300,1.69e-04,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0070268; GO:0031424; GO:0009615
SLAMF7,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.300,4.57e-04,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
APOL6,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',3.300,9.12e-12,normal; injection of interferon gamma,normal; none,GO:0009615
CX3CL1,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',3.300,9.55e-10,normal; injection of interferon gamma,normal; none,
FCN1,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',3.300,3.28e-09,normal; injection of interferon gamma,normal; none,
IFIT2,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',3.300,2.80e-09,normal; injection of interferon gamma,normal; none,GO:0009615
IL12RB2,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',3.300,8.01e-09,normal; injection of interferon gamma,normal; none,
IRF7,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',3.300,1.18e-09,normal; injection of interferon gamma,normal; none,GO:0009615
TRIM22,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',3.300,5.17e-10,normal; injection of interferon gamma,normal; none,GO:0009615
IFIT2,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',3.300,7.88e-13,psoriasis; injection of interferon gamma,psoriasis; none,GO:0009615
UBE2L6,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',3.300,7.19e-15,psoriasis; injection of interferon gamma,psoriasis; none,GO:0009615
ACP7,E-GEOD-41745,'lesional' vs 'non-lesional',3.300,2.95e-23,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
VNN3,E-GEOD-41745,'lesional' vs 'non-lesional',3.300,1.42e-12,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
CCL20,E-GEOD-53552,'lesional' vs 'non-lesional' in 'none' at '0 day',3.300,5.84e-13,0 day; lesional; none,0 day; non-lesional; none,
GZMB,E-GEOD-53552,'lesional' vs 'non-lesional' in 'none' at '0 day',3.300,2.78e-12,0 day; lesional; none,0 day; non-lesional; none,GO:0009615
IL19,E-GEOD-53552,'lesional' vs 'non-lesional' in 'none' at '0 day',3.300,2.42e-13,0 day; lesional; none,0 day; non-lesional; none,
OASL,E-GEOD-53552,'lesional' vs 'non-lesional' in 'none' at '0 day',3.300,2.42e-13,0 day; lesional; none,0 day; non-lesional; none,GO:0070268; GO:0031424; GO:0009615
GZMB,E-GEOD-41662,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',3.300,3.10e-12,lesional,non-lesional,GO:0009615
IL19,E-GEOD-41662,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',3.300,1.31e-13,lesional,non-lesional,
KYNU,E-GEOD-50790,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',3.300,8.50e-04,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
OASL,E-GEOD-41662,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',3.300,8.64e-13,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
OASL,E-GEOD-34248,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',3.300,9.39e-07,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
OASL,E-GEOD-52471,'psoriasis' vs 'normal' in 'Affy RNA amplification kit',3.300,1.41e-10,Affy RNA amplification kit; psoriasis,Affy RNA amplification kit; normal,GO:0070268; GO:0031424; GO:0009615
TYMP,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',3.300,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424; GO:0009615
GZMA,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.200,6.33e-05,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
HERC6,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.200,1.88e-05,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
IFI44,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.200,1.68e-06,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
HERC5,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',3.200,1.01e-09,normal; injection of interferon gamma,normal; none,GO:0009615
PSMB9,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',3.200,4.80e-11,normal; injection of interferon gamma,normal; none,
SLAMF8,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',3.200,3.86e-08,normal; injection of interferon gamma,normal; none,
STAT1,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',3.200,4.89e-12,normal; injection of interferon gamma,normal; none,GO:0070268; GO:0031424; GO:0002376; GO:0009615
TAP1,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',3.200,1.14e-11,normal; injection of interferon gamma,normal; none,
APOL3,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',3.200,1.50e-13,psoriasis; injection of interferon gamma,psoriasis; none,
APOL6,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',3.200,2.20e-14,psoriasis; injection of interferon gamma,psoriasis; none,GO:0009615
BCL2A1,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',3.200,4.35e-12,psoriasis; injection of interferon gamma,psoriasis; none,
DDX60,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',3.200,7.53e-13,psoriasis; injection of interferon gamma,psoriasis; none,GO:0009615
IL12RB2,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',3.200,2.68e-11,psoriasis; injection of interferon gamma,psoriasis; none,
IRF7,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',3.200,6.05e-14,psoriasis; injection of interferon gamma,psoriasis; none,GO:0009615
PLSCR1,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',3.200,7.36e-13,psoriasis; injection of interferon gamma,psoriasis; none,GO:0009615
TAP1,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',3.200,1.87e-14,psoriasis; injection of interferon gamma,psoriasis; none,
GZMB,E-GEOD-30999,'lesional' vs 'non-lesional',3.200,0.00e+00,lesional,non-lesional,GO:0009615
KLK13,E-GEOD-30999,'lesional' vs 'non-lesional',3.200,0.00e+00,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
KYNU,E-GEOD-41745,'lesional' vs 'non-lesional',3.200,1.09e-40,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
OASL,E-GEOD-41745,'lesional' vs 'non-lesional',3.200,1.82e-12,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
PRSS27,E-GEOD-30999,'lesional' vs 'non-lesional',3.200,0.00e+00,lesional,non-lesional,
SPRR2A,E-GEOD-41745,'lesional' vs 'non-lesional',3.200,6.76e-11,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
KRT16,E-GEOD-53552,'lesional' vs 'non-lesional' in 'none' at '0 day',3.200,6.50e-22,0 day; lesional; none,0 day; non-lesional; none,GO:0070268; GO:0031424; GO:0009615
KRT16,E-GEOD-41662,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',3.200,1.76e-21,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
KYNU,E-GEOD-34248,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',3.200,2.71e-08,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
SPRR2A,E-GEOD-50790,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',3.200,7.08e-04,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
TRIM10,E-GEOD-50790,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',3.200,2.16e-03,lesional,non-lesional,
CHI3L2,E-GEOD-52471,'psoriasis' vs 'normal' in 'Affy RNA amplification kit',3.200,9.09e-10,Affy RNA amplification kit; psoriasis,Affy RNA amplification kit; normal,
EHF,E-GEOD-52471,'psoriasis' vs 'normal' in 'Affy RNA amplification kit',3.200,1.18e-10,Affy RNA amplification kit; psoriasis,Affy RNA amplification kit; normal,GO:0070268; GO:0031424; GO:0009615
GNA15,E-GEOD-52471,'psoriasis' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.200,2.44e-05,Ovation RNA Amplification V2 kit; psoriasis,Ovation RNA Amplification V2 kit; normal,
PPP4C,E-GEOD-52471,'psoriasis' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.200,1.28e-05,Ovation RNA Amplification V2 kit; psoriasis,Ovation RNA Amplification V2 kit; normal,
ZC3H12A,E-GEOD-52471,'psoriasis' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.200,2.97e-05,Ovation RNA Amplification V2 kit; psoriasis,Ovation RNA Amplification V2 kit; normal,GO:0070268; GO:0031424; GO:0009615
HRH2,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',3.200,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424; GO:0009615
NWD2,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',3.200,0.00e+00,lesional skin; psoriasis,normal; normal,
SAMD9,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',3.200,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424; GO:0009615
KYNU,E-GEOD-41663,'skin lesion' vs 'normal skin' in 'none' at '0 weeks',3.200,9.98e-09,none; skin lesion; 0 week,none; normal; 0 week,GO:0070268; GO:0031424; GO:0009615
HERC5,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.100,2.45e-04,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
LAIR1,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.100,1.53e-05,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
LIPG,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.100,2.15e-04,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
OAS1,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.100,1.41e-05,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0070268; GO:0031424; GO:0009615
ZBP1,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.100,9.66e-05,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
APOL2,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',3.100,4.46e-11,normal; injection of interferon gamma,normal; none,
APOL3,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',3.100,5.81e-10,normal; injection of interferon gamma,normal; none,
LAP3,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',3.100,7.62e-11,normal; injection of interferon gamma,normal; none,GO:0009615
APOL2,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',3.100,9.21e-13,psoriasis; injection of interferon gamma,psoriasis; none,
BST2,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',3.100,1.70e-11,psoriasis; injection of interferon gamma,psoriasis; none,GO:0009615
CTSS,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',3.100,1.71e-12,psoriasis; injection of interferon gamma,psoriasis; none,
HERC5,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',3.100,1.06e-09,psoriasis; injection of interferon gamma,psoriasis; none,GO:0009615
PSMB9,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',3.100,2.54e-12,psoriasis; injection of interferon gamma,psoriasis; none,
SAMHD1,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',3.100,4.91e-12,psoriasis; injection of interferon gamma,psoriasis; none,GO:0009615
ADAMDEC1,E-GEOD-30999,'lesional' vs 'non-lesional',3.100,5.71e-42,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
ADGRF1,E-GEOD-41745,'lesional' vs 'non-lesional',3.100,1.03e-10,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
AKR1B10,E-GEOD-41745,'lesional' vs 'non-lesional',3.100,1.13e-18,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
C10orf99,E-GEOD-30999,'lesional' vs 'non-lesional',3.100,1.63e-40,lesional,non-lesional,
FOXE1,E-GEOD-30999,'lesional' vs 'non-lesional',3.100,0.00e+00,lesional,non-lesional,
HYAL4,E-GEOD-30999,'lesional' vs 'non-lesional',3.100,0.00e+00,lesional,non-lesional,
REN,E-GEOD-30999,'lesional' vs 'non-lesional',3.100,9.80e-45,lesional,non-lesional,
RHCG,E-GEOD-41745,'lesional' vs 'non-lesional',3.100,5.42e-12,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
SLC6A14,E-GEOD-41745,'lesional' vs 'non-lesional',3.100,0.00e+00,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
CTA-384D8.35,E-GEOD-53552,'lesional' vs 'non-lesional' in 'none' at '0 day',3.100,1.21e-14,0 day; lesional; none,0 day; non-lesional; none,
KLHDC7B-DT,E-GEOD-53552,'lesional' vs 'non-lesional' in 'none' at '0 day',3.100,1.21e-14,0 day; lesional; none,0 day; non-lesional; none,
U62317.1,E-GEOD-53552,'lesional' vs 'non-lesional' in 'none' at '0 day',3.100,1.21e-14,0 day; lesional; none,0 day; non-lesional; none,
U62317.2,E-GEOD-53552,'lesional' vs 'non-lesional' in 'none' at '0 day',3.100,1.21e-14,0 day; lesional; none,0 day; non-lesional; none,
ADGRF1,E-GEOD-41662,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',3.100,7.73e-20,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
CHRNA9,E-GEOD-34248,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',3.100,8.45e-08,lesional,non-lesional,
CTA-384D8.35,E-GEOD-41662,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',3.100,4.30e-14,lesional,non-lesional,
FOXE1,E-GEOD-50790,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',3.100,1.78e-03,lesional,non-lesional,
HYAL4,E-GEOD-34248,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',3.100,2.85e-06,lesional,non-lesional,
KLHDC7B-DT,E-GEOD-41662,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',3.100,4.30e-14,lesional,non-lesional,
KRT16,E-GEOD-50790,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',3.100,4.70e-04,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
LINC01215,E-GEOD-50790,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',3.100,1.48e-03,lesional,non-lesional,
U62317.1,E-GEOD-41662,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',3.100,4.30e-14,lesional,non-lesional,
U62317.2,E-GEOD-41662,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',3.100,4.30e-14,lesional,non-lesional,
ACP3,E-GEOD-52471,'psoriasis' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.100,2.58e-05,Ovation RNA Amplification V2 kit; psoriasis,Ovation RNA Amplification V2 kit; normal,
ACPP,E-GEOD-52471,'psoriasis' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.100,2.58e-05,Ovation RNA Amplification V2 kit; psoriasis,Ovation RNA Amplification V2 kit; normal,
LONP1,E-GEOD-52471,'psoriasis' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.100,8.44e-06,Ovation RNA Amplification V2 kit; psoriasis,Ovation RNA Amplification V2 kit; normal,
LTBP3,E-GEOD-52471,'psoriasis' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.100,1.13e-05,Ovation RNA Amplification V2 kit; psoriasis,Ovation RNA Amplification V2 kit; normal,
SNRPB,E-GEOD-52471,'psoriasis' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.100,1.03e-05,Ovation RNA Amplification V2 kit; psoriasis,Ovation RNA Amplification V2 kit; normal,
SERPINB13,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',3.100,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424; GO:0009615
CTA-384D8.35,E-GEOD-41663,'skin lesion' vs 'normal skin' in 'none' at '0 weeks',3.100,9.64e-09,none; skin lesion; 0 week,none; normal; 0 week,
GZMB,E-GEOD-41663,'skin lesion' vs 'normal skin' in 'none' at '0 weeks',3.100,9.98e-09,none; skin lesion; 0 week,none; normal; 0 week,GO:0009615
KLHDC7B-DT,E-GEOD-41663,'skin lesion' vs 'normal skin' in 'none' at '0 weeks',3.100,9.64e-09,none; skin lesion; 0 week,none; normal; 0 week,
U62317.1,E-GEOD-41663,'skin lesion' vs 'normal skin' in 'none' at '0 weeks',3.100,9.64e-09,none; skin lesion; 0 week,none; normal; 0 week,
U62317.2,E-GEOD-41663,'skin lesion' vs 'normal skin' in 'none' at '0 weeks',3.100,9.64e-09,none; skin lesion; 0 week,none; normal; 0 week,
CD2,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.000,2.25e-04,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
IFIH1,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.000,4.56e-06,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
IL7R,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.000,2.86e-04,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0070268; GO:0031424; GO:0009615
IRF7,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.000,2.70e-04,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
ITGAL,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.000,8.28e-05,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
MS4A4A,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.000,5.06e-04,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
NKG7,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.000,7.32e-05,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
SAMSN1,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.000,5.91e-04,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
CSAG3,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',3.000,3.37e-10,normal; injection of interferon gamma,normal; none,
GBP2,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',3.000,3.26e-10,normal; injection of interferon gamma,normal; none,
GCH1,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',3.000,1.18e-09,normal; injection of interferon gamma,normal; none,
VAMP5,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',3.000,5.14e-09,normal; injection of interferon gamma,normal; none,
APOBEC3G,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',3.000,8.77e-12,psoriasis; injection of interferon gamma,psoriasis; none,GO:0009615
GBP2,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',3.000,4.78e-12,psoriasis; injection of interferon gamma,psoriasis; none,
IFI27,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',3.000,1.12e-11,psoriasis; injection of interferon gamma,psoriasis; none,GO:0009615
VAMP5,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',3.000,4.25e-12,psoriasis; injection of interferon gamma,psoriasis; none,
CHRNA9,E-GEOD-30999,'lesional' vs 'non-lesional',3.000,2.52e-42,lesional,non-lesional,
IL19,E-GEOD-30999,'lesional' vs 'non-lesional',3.000,8.53e-43,lesional,non-lesional,
TYMP,E-GEOD-41745,'lesional' vs 'non-lesional',3.000,3.73e-15,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
ADAMDEC1,E-GEOD-53552,'lesional' vs 'non-lesional' in 'none' at '0 day',3.000,5.63e-13,0 day; lesional; none,0 day; non-lesional; none,GO:0070268; GO:0031424; GO:0009615
CCNB1,E-GEOD-26866,'lesional' vs 'non-lesional' in 'one-cycle cDNA synthesis from bulk tissue',3.000,6.20e-03,lesional; one-cycle cDNA synthesis from bulk tissue,non-lesional; one-cycle cDNA synthesis from bulk tissue,
ADAMDEC1,E-GEOD-41662,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',3.000,5.18e-13,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
CXCL17,E-GEOD-50790,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',3.000,1.31e-03,lesional,non-lesional,
HPSE,E-GEOD-34248,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',3.000,5.80e-07,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
KRT16,E-GEOD-34248,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',3.000,5.60e-08,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
CCL20,E-GEOD-52471,'psoriasis' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.000,1.95e-05,Ovation RNA Amplification V2 kit; psoriasis,Ovation RNA Amplification V2 kit; normal,
GNB2,E-GEOD-52471,'psoriasis' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.000,1.07e-05,Ovation RNA Amplification V2 kit; psoriasis,Ovation RNA Amplification V2 kit; normal,
UQCRC1,E-GEOD-52471,'psoriasis' vs 'normal' in 'Ovation RNA Amplification V2 kit',3.000,1.08e-05,Ovation RNA Amplification V2 kit; psoriasis,Ovation RNA Amplification V2 kit; normal,
CTLA4,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',3.000,0.00e+00,lesional skin; psoriasis,normal; normal,
FOXE1,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',3.000,0.00e+00,lesional skin; psoriasis,normal; normal,
FUT3,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',3.000,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424; GO:0009615
GBP6,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',3.000,0.00e+00,lesional skin; psoriasis,normal; normal,
GJB6,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',3.000,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424; GO:0009615
INA,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',3.000,0.00e+00,lesional skin; psoriasis,normal; normal,
SLC26A9,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',3.000,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424; GO:0009615
UPP1,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',3.000,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424; GO:0009615
ADGRF1,E-GEOD-41663,'skin lesion' vs 'normal skin' in 'none' at '0 weeks',3.000,1.46e-08,none; skin lesion; 0 week,none; normal; 0 week,GO:0070268; GO:0031424; GO:0009615
CHRNA9,E-GEOD-41663,'skin lesion' vs 'normal skin' in 'none' at '0 weeks',3.000,4.25e-08,none; skin lesion; 0 week,none; normal; 0 week,
CD53,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',2.900,2.62e-05,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
GBP1,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',2.900,3.02e-04,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0070268; GO:0031424; GO:0002376; GO:0009615
GPR65,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',2.900,9.66e-05,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
IL24,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',2.900,2.70e-04,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
LILRA4,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',2.900,5.04e-04,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
MICB,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',2.900,1.06e-04,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
PRF1,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',2.900,5.72e-05,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
PRKCQ,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',2.900,3.26e-04,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
SPRR1A,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',2.900,7.21e-05,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0070268; GO:0031424; GO:0009615
APOBEC3G,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',2.900,1.14e-11,normal; injection of interferon gamma,normal; none,GO:0009615
IL15,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',2.900,3.41e-11,normal; injection of interferon gamma,normal; none,
IL32,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',2.900,2.78e-08,normal; injection of interferon gamma,normal; none,
NMI,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',2.900,2.41e-10,normal; injection of interferon gamma,normal; none,GO:0009615
CSAG3,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',2.900,7.18e-11,psoriasis; injection of interferon gamma,psoriasis; none,
GCH1,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',2.900,6.04e-11,psoriasis; injection of interferon gamma,psoriasis; none,
IL32,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',2.900,1.72e-13,psoriasis; injection of interferon gamma,psoriasis; none,
STAT1,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',2.900,7.88e-13,psoriasis; injection of interferon gamma,psoriasis; none,GO:0070268; GO:0031424; GO:0002376; GO:0009615
TRIM22,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',2.900,1.84e-12,psoriasis; injection of interferon gamma,psoriasis; none,GO:0009615
ADAMDEC1,E-GEOD-41745,'lesional' vs 'non-lesional',2.900,4.01e-14,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
LINC01215,E-GEOD-30999,'lesional' vs 'non-lesional',2.900,8.38e-43,lesional,non-lesional,
VNN1,E-GEOD-30999,'lesional' vs 'non-lesional',2.900,0.00e+00,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
ARSF,E-GEOD-53552,'lesional' vs 'non-lesional' in 'none' at '0 day',2.900,6.25e-21,0 day; lesional; none,0 day; non-lesional; none,GO:0070268; GO:0031424; GO:0009615
CNFN,E-GEOD-53552,'lesional' vs 'non-lesional' in 'none' at '0 day',2.900,7.26e-13,0 day; lesional; none,0 day; non-lesional; none,GO:0070268; GO:0031424; GO:0009615
PRSS27,E-GEOD-53552,'lesional' vs 'non-lesional' in 'none' at '0 day',2.900,1.67e-17,0 day; lesional; none,0 day; non-lesional; none,
VNN1,E-GEOD-53552,'lesional' vs 'non-lesional' in 'none' at '0 day',2.900,5.31e-13,0 day; lesional; none,0 day; non-lesional; none,GO:0070268; GO:0031424; GO:0009615
KYNU,E-GEOD-26866,'lesional' vs 'non-lesional' in 'two-cycle cDNA synthesis from sliced tissue section',2.900,2.43e-03,lesional; two-cycle cDNA synthesis from sliced tissue section,non-lesional; two-cycle cDNA synthesis from sliced tissue section,GO:0070268; GO:0031424; GO:0009615
ARSF,E-GEOD-41662,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',2.900,1.91e-20,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
CNFN,E-GEOD-41662,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',2.900,1.20e-12,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
CTA-384D8.35,E-GEOD-34248,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',2.900,4.17e-06,lesional,non-lesional,
IL36A,E-GEOD-34248,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',2.900,9.36e-06,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
IL36RN,E-GEOD-41662,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',2.900,2.20e-12,lesional,non-lesional,
KLHDC7B-DT,E-GEOD-34248,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',2.900,4.17e-06,lesional,non-lesional,
LINC01215,E-GEOD-41662,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',2.900,5.21e-15,lesional,non-lesional,
U62317.1,E-GEOD-34248,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',2.900,4.17e-06,lesional,non-lesional,
U62317.2,E-GEOD-34248,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',2.900,4.17e-06,lesional,non-lesional,
VNN1,E-GEOD-41662,'psoriasis lesional skin' vs 'psoriasis non-lesional skin',2.900,1.48e-12,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
IL36RN,E-GEOD-52471,'psoriasis' vs 'normal' in 'Affy RNA amplification kit',2.900,1.76e-11,Affy RNA amplification kit; psoriasis,Affy RNA amplification kit; normal,
SERPINB13,E-GEOD-52471,'psoriasis' vs 'normal' in 'Affy RNA amplification kit',2.900,1.22e-10,Affy RNA amplification kit; psoriasis,Affy RNA amplification kit; normal,GO:0070268; GO:0031424; GO:0009615
TMPRSS11D,E-GEOD-52471,'psoriasis' vs 'normal' in 'Affy RNA amplification kit',2.900,7.50e-10,Affy RNA amplification kit; psoriasis,Affy RNA amplification kit; normal,GO:0070268; GO:0031424; GO:0009615
MAP3K6,E-GEOD-52471,'psoriasis' vs 'normal' in 'Ovation RNA Amplification V2 kit',2.900,2.68e-05,Ovation RNA Amplification V2 kit; psoriasis,Ovation RNA Amplification V2 kit; normal,
RPL35P8,E-GEOD-52471,'psoriasis' vs 'normal' in 'Ovation RNA Amplification V2 kit',2.900,2.68e-05,Ovation RNA Amplification V2 kit; psoriasis,Ovation RNA Amplification V2 kit; normal,
SLC38A10,E-GEOD-52471,'psoriasis' vs 'normal' in 'Ovation RNA Amplification V2 kit',2.900,2.68e-05,Ovation RNA Amplification V2 kit; psoriasis,Ovation RNA Amplification V2 kit; normal,
DSC2,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',2.900,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424; GO:0009615
HAS3,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',2.900,0.00e+00,lesional skin; psoriasis,normal; normal,
HPSE,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',2.900,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424; GO:0009615
IL36RN,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',2.900,0.00e+00,lesional skin; psoriasis,normal; normal,
LINC01605,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',2.900,0.00e+00,lesional skin; psoriasis,normal; normal,
SLC7A11,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',2.900,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424; GO:0009615
TMC5,E-GEOD-54456,'psoriasis; lesional skin' vs 'normal; normal',2.900,0.00e+00,lesional skin; psoriasis,normal; normal,GO:0070268; GO:0031424; GO:0009615
KLK13,E-GEOD-41663,'skin lesion' vs 'normal skin' in 'none' at '0 weeks',2.900,3.34e-08,none; skin lesion; 0 week,none; normal; 0 week,GO:0070268; GO:0031424; GO:0009615
CD3G,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',2.800,2.51e-04,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
SLAMF1,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',2.800,5.92e-04,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
SP140,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',2.800,5.25e-04,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0009615
XAF1,E-GEOD-52471,'cutaneous lupus erythematosus' vs 'normal' in 'Ovation RNA Amplification V2 kit',2.800,8.16e-06,Ovation RNA Amplification V2 kit; cutaneous lupus erythematosus,Ovation RNA Amplification V2 kit; normal,GO:0070268; GO:0031424; GO:0009615
BCL2A1,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',2.800,1.53e-09,normal; injection of interferon gamma,normal; none,
ETV7,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',2.800,1.44e-10,normal; injection of interferon gamma,normal; none,
IFIT5,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',2.800,6.61e-10,normal; injection of interferon gamma,normal; none,GO:0009615
PARP12,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',2.800,9.97e-11,normal; injection of interferon gamma,normal; none,GO:0009615
SAMHD1,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',2.800,6.58e-08,normal; injection of interferon gamma,normal; none,GO:0009615
SNX10,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'normal',2.800,4.71e-10,normal; injection of interferon gamma,normal; none,
ETV7,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',2.800,1.33e-10,psoriasis; injection of interferon gamma,psoriasis; none,
IL15,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',2.800,1.59e-11,psoriasis; injection of interferon gamma,psoriasis; none,
NMI,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',2.800,1.29e-11,psoriasis; injection of interferon gamma,psoriasis; none,GO:0009615
SNX10,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',2.800,8.31e-10,psoriasis; injection of interferon gamma,psoriasis; none,
SP110,E-GEOD-32407,'injection of interferon gamma' vs 'none' in 'psoriasis',2.800,2.16e-12,psoriasis; injection of interferon gamma,psoriasis; none,GO:0009615
ARSF,E-GEOD-41745,'lesional' vs 'non-lesional',2.800,1.30e-14,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
CYP24A1,E-GEOD-30999,'lesional' vs 'non-lesional',2.800,1.40e-45,lesional,non-lesional,
S100A7A,E-GEOD-41745,'lesional' vs 'non-lesional',2.800,3.28e-08,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
SPRR1A,E-GEOD-41745,'lesional' vs 'non-lesional',2.800,2.05e-22,lesional,non-lesional,GO:0070268; GO:0031424; GO:0009615
AL603756.1,E-GEOD-53552,'lesional' vs 'non-lesional' in 'none' at '0 day',2.800,4.97e-15,0 day; lesional; none,0 day; non-lesional; none,
IL36RN,E-GEOD-53552,'lesional' vs 'non-lesional' in 'none' at '0 day',2.800,9.46e-13,0 day; lesional; none,0 day; non-lesional; none,
LINC01215,E-GEOD-53552,'lesional' vs 'non-lesional' in 'none' at '0 day',2.800,4.54e-15,0 day; lesional; none,0 day; non-lesional; none,
RP11-338I21.1,E-GEOD-53552,'lesional' vs 'non-lesional' in 'none' at '0 day',2.800,4.97e-15,0 day; lesional; none,0 day; non-lesional; none,
TGM1,E-GEOD-53552,'lesional' vs 'non-lesional' in 'none' at '0 day',2.800,2.92e-16,0 day; lesional; none,0 day; non-lesional; none,GO:0070268; GO:0031424; GO:0009615
